Clinical trials
Pulmonary Embolism trials in Turkey (Türkiye)
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Unknown status | 5 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 3 |
| Bristol-Myers Squibb | 2 |
| Daiichi Sankyo | 2 |
| Marmara University Pendik Training and Research Hospital | 2 |
| Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital | 1 |
| Ankara University | 1 |
| Antalya Health Sciences University | 1 |
| Aysel Sünnetçioğlu | 1 |
| Bezmialem Vakif University | 1 |
| Boston Scientific Corporation | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pulmonary Embolism | 30 |
| Venous Thrombosis | 11 |
| Venous Thromboembolism | 7 |
| Thromboembolism | 6 |
| Thrombosis | 6 |
| COVID-19 | 3 |
| Acute Kidney Injury | 1 |
| Aortic Dissection | 1 |
| Atrial Fibrillation | 1 |
| Brain Infarction | 1 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.